CYTOMX THERAPEUTICS INC Sustainability Profile
CytomX Therapeutics Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2011, the company has made significant strides in the field of protein engineering, focusing on its proprietary Probody™ platform, which enables the creation of targeted therapies that minimise off-target effects. CytomX operates primarily in the oncology sector, with a commitment to advancing treatments that enhance patient outcomes. The company has achieved notable milestones, including strategic partnerships with major pharmaceutical firms, which bolster its position in the competitive biopharmaceutical landscape. With a robust pipeline of unique therapeutics, CytomX Therapeutics continues to redefine cancer treatment paradigms, making it a key player in the industry.
DitchCarbon Score
How does CYTOMX THERAPEUTICS INC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CYTOMX THERAPEUTICS INC's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CYTOMX THERAPEUTICS INC's reported carbon emissions
CytomX Therapeutics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, CytomX Therapeutics has not inherited any emissions data from a parent or related organization, which means their climate commitments and performance metrics are not influenced by external corporate family relationships. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. However, without specific data or commitments from CytomX Therapeutics, it is unclear how they align with these industry trends.
How Carbon Intensive is CYTOMX THERAPEUTICS INC's Industry?
How Carbon Intensive is CYTOMX THERAPEUTICS INC's Location?
CYTOMX THERAPEUTICS INC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CYTOMX THERAPEUTICS INC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
